Infant weight growth velocity patterns and general and abdominal adiposity in school-age children. The Generation R

C J Kruithof1,2, O Gishti1,2,3, A Hofman2

  • 1The Generation R Study Group, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Insights

Infant weight growth velocity patterns, including peak weight velocity (PWV) and body mass index at adiposity peak (BMIAP), are linked to higher childhood adiposity and overweight risk. These findings highlight the importance of monitoring infant growth for predicting later health outcomes.

Area of Science:

  • Pediatric Endocrinology
  • Growth and Development
  • Public Health Nutrition

Background:

  • Understanding infant growth patterns is crucial for predicting childhood obesity.
  • Early life weight gain velocity may influence long-term adiposity.

Purpose of the Study:

  • To investigate the association between infant weight growth velocity patterns and childhood adiposity.
  • To determine if infant growth metrics predict general and abdominal fat measures in children.

Main Methods:

  • Population-based prospective cohort study of 5126 children.
  • Analysis of growth measurements from 0 to 3 years to derive peak weight velocity (PWV), age at adiposity peak (AGEAP), and body mass index at adiposity peak (BMIAP).
  • Assessment of childhood adiposity using dual-energy X-ray absorptiometry and abdominal ultrasound at a median age of 6.0 years.

Main Results:

  • Higher infant PWV and BMIAP were significantly associated with increased childhood BMI, body fat percentage, android/gynoid fat ratio, and abdominal fat.
  • Infant AGEAP in the highest tertile was linked to higher adiposity in girls.
  • Increased infant PWV and BMIAP correlated with a higher risk of childhood overweight, particularly in girls.

Conclusions:

  • Rapid infant weight gain velocity and peak adiposity are associated with adverse body composition and increased overweight risk in school-aged children.
  • Infant growth patterns may serve as important predictors of later overweight status.
  • Further research is needed to explore the predictive value of infant growth patterns for childhood overweight.
Abstract

Related Concept Videos

Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
1.9K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
669
Changes in the Appendicular Skeleton with Age01:09

Changes in the Appendicular Skeleton with Age

The upper and lower limb initially develops as a small bulge called a limb bud, which appears on the lateral side of the early embryo. The upper limb bud appears near the end of the fourth week of development, with the lower limb bud appearing shortly after.
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
4.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
441
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
363
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
317